Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis

By Nishimura Reiki  

Breast Cancer, Vol. 17, Iss. 4, 2010-10 ,pp. : 269-275

Springer Publishing Company

Access to resources Recommend Favorite

Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1046-1054

Spandidos Publications

Access to resources Recommend Favorite

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

By Delpech Y.  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 619-627

Springer Publishing Company

Access to resources Recommend Favorite

The Use of Digital Images Improves Reproducibility of the Ki-67 Labeling Index as a Proliferation Marker in Breast Cancer

By Vörös András   Csörgő Erika   Kővári Bence   Lázár Péter   Kelemen Gyöngyi   Cserni Gábor  

Pathology & Oncology Research, Vol. 20, Iss. 2, 2014-04 ,pp. : 391-397

Springer Publishing Company

Access to resources Recommend Favorite

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite